NZ Immuno-Oncology Research Review Issue 31
In this issue:
– Disparities in immunotherapy use for triple-negative breast cancer
– Efficacy and safety of ICIs in elderly patients with advanced NSCLC
– OS better in NSCLC when immunochemotherapy is administered in the morning
– Nivolumab-ipilimumab in microsatellite-instability-high metastatic colorectal cancer
– Burden and clinical trajectory of ICI-induced endocrinopathies
– First-line chemotherapy ± ICI for advanced gastric cancer
– Nervous system events associated with blinatumomab
– Induced pluripotent stem-cell-derived CD19-directed CAR NK cells for B-cell lymphoma
– 10-year outcomes for nivolumab-ipilimumab in advanced melanoma
– Talquetamab-teclistamab for relapsed/refractory multiple myeloma
Expert contributor
Professor Roslyn Kemp
Professor Roslyn Kemp (BSc Hons, Otago [1997], PhD, Otago, Malaghan Institute [2001]) is a researcher who has a particular interest in colorectal cancer and gut-specific immune responses in health and disease. Her current research focus involves T-cell and myeloid cell subsets in people with colorectal cancer and inflammatory bowel disease, and aims to improve diagnosis, […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.
